King's College London

Research portal

Global public and philanthropic investment in childhood cancer research: systematic analysis of research funding, 2008–16

Research output: Contribution to journalReview article

Standard

Global public and philanthropic investment in childhood cancer research : systematic analysis of research funding, 2008–16. / Loucaides, Eva M.; Fitchett, Elizabeth J.A.; Sullivan, Richard; Atun, Rifat.

In: The Lancet Oncology, Vol. 20, No. 12, 12.2019, p. 672-684.

Research output: Contribution to journalReview article

Harvard

Loucaides, EM, Fitchett, EJA, Sullivan, R & Atun, R 2019, 'Global public and philanthropic investment in childhood cancer research: systematic analysis of research funding, 2008–16', The Lancet Oncology, vol. 20, no. 12, pp. 672-684. https://doi.org/10.1016/S1470-2045(19)30662-X

APA

Loucaides, E. M., Fitchett, E. J. A., Sullivan, R., & Atun, R. (2019). Global public and philanthropic investment in childhood cancer research: systematic analysis of research funding, 2008–16. The Lancet Oncology, 20(12), 672-684. https://doi.org/10.1016/S1470-2045(19)30662-X

Vancouver

Loucaides EM, Fitchett EJA, Sullivan R, Atun R. Global public and philanthropic investment in childhood cancer research: systematic analysis of research funding, 2008–16. The Lancet Oncology. 2019 Dec;20(12):672-684. https://doi.org/10.1016/S1470-2045(19)30662-X

Author

Loucaides, Eva M. ; Fitchett, Elizabeth J.A. ; Sullivan, Richard ; Atun, Rifat. / Global public and philanthropic investment in childhood cancer research : systematic analysis of research funding, 2008–16. In: The Lancet Oncology. 2019 ; Vol. 20, No. 12. pp. 672-684.

Bibtex Download

@article{ee1e7ae07c5f46f38f097db85742ffa6,
title = "Global public and philanthropic investment in childhood cancer research: systematic analysis of research funding, 2008–16",
abstract = "Childhood cancers caused an estimated 75 000 deaths in children aged 0–14 years in 2018, of which 90% were in low-income and middle-income countries, and yet this group is missing from global health agendas. We examined global patterns in public and philanthropic funding for childhood cancer research—a proxy for global research activity—to address the critical gaps in knowledge. We used data from the Dimensions database to systematically search for and analyse 3414 grants from 115 funders across 35 countries between 2008 and 2016, organised by funding source, recipient, tumour type, research focus, and pipeline categories, to investigate trends over time. During this period, global funding for childhood cancer research was US$2 billion, of which $772 million (37·9%) was for general childhood cancer, $449 million (22·0%) was for leukaemias, and $330 million (16·2%) was for CNS tumours. $1·6 billion (77·7%) of funding was awarded from, and to, institutions based in the USA. Preclinical research received $1·2 billion (59·3%), and around $525 million (25·7%) included support for clinical trials, but only $113 million (5·5%) supported health-care delivery research. Overall, funding was inadequate and geographically inequitable, and new commitments to funding have declined since 2011.",
author = "Loucaides, {Eva M.} and Fitchett, {Elizabeth J.A.} and Richard Sullivan and Rifat Atun",
year = "2019",
month = dec,
doi = "10.1016/S1470-2045(19)30662-X",
language = "English",
volume = "20",
pages = "672--684",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "12",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Global public and philanthropic investment in childhood cancer research

T2 - systematic analysis of research funding, 2008–16

AU - Loucaides, Eva M.

AU - Fitchett, Elizabeth J.A.

AU - Sullivan, Richard

AU - Atun, Rifat

PY - 2019/12

Y1 - 2019/12

N2 - Childhood cancers caused an estimated 75 000 deaths in children aged 0–14 years in 2018, of which 90% were in low-income and middle-income countries, and yet this group is missing from global health agendas. We examined global patterns in public and philanthropic funding for childhood cancer research—a proxy for global research activity—to address the critical gaps in knowledge. We used data from the Dimensions database to systematically search for and analyse 3414 grants from 115 funders across 35 countries between 2008 and 2016, organised by funding source, recipient, tumour type, research focus, and pipeline categories, to investigate trends over time. During this period, global funding for childhood cancer research was US$2 billion, of which $772 million (37·9%) was for general childhood cancer, $449 million (22·0%) was for leukaemias, and $330 million (16·2%) was for CNS tumours. $1·6 billion (77·7%) of funding was awarded from, and to, institutions based in the USA. Preclinical research received $1·2 billion (59·3%), and around $525 million (25·7%) included support for clinical trials, but only $113 million (5·5%) supported health-care delivery research. Overall, funding was inadequate and geographically inequitable, and new commitments to funding have declined since 2011.

AB - Childhood cancers caused an estimated 75 000 deaths in children aged 0–14 years in 2018, of which 90% were in low-income and middle-income countries, and yet this group is missing from global health agendas. We examined global patterns in public and philanthropic funding for childhood cancer research—a proxy for global research activity—to address the critical gaps in knowledge. We used data from the Dimensions database to systematically search for and analyse 3414 grants from 115 funders across 35 countries between 2008 and 2016, organised by funding source, recipient, tumour type, research focus, and pipeline categories, to investigate trends over time. During this period, global funding for childhood cancer research was US$2 billion, of which $772 million (37·9%) was for general childhood cancer, $449 million (22·0%) was for leukaemias, and $330 million (16·2%) was for CNS tumours. $1·6 billion (77·7%) of funding was awarded from, and to, institutions based in the USA. Preclinical research received $1·2 billion (59·3%), and around $525 million (25·7%) included support for clinical trials, but only $113 million (5·5%) supported health-care delivery research. Overall, funding was inadequate and geographically inequitable, and new commitments to funding have declined since 2011.

UR - http://www.scopus.com/inward/record.url?scp=85075711966&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(19)30662-X

DO - 10.1016/S1470-2045(19)30662-X

M3 - Review article

C2 - 31797794

AN - SCOPUS:85075711966

VL - 20

SP - 672

EP - 684

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 12

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454